Contact Us
Drug Search Results
More Filters [+]

CAZ-104

Alternative Names: caz-104, caz104, caz 104
Latest Update: 2017-09-01
Latest Update Note: Clinical Trial Update

Product Description

Ceftazidime-NXL104 was active against strains with the OXA-48 enzyme or with combinations of impermeability and an extended-spectrum _-lactamase (ESBL) or AmpC enzyme and also against most Klebsiella spp.

Mechanisms of Action: LACTB Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CAZ-104

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Urinary Tract Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
D4280C00011

P1

Completed

Urinary Tract Infections

2012-10-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions